Signalling pathways of the TNF superfamily: A double-edged sword

被引:2134
作者
Aggarwal, BB [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Cytokine Res Stn, Dept Bioimmunotherapy, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nri1184
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Two different tumour-necrosis factors (TNFs), first isolated in 1984, were found to be cytotoxic to tumour cells and to induce tumour regression in mice. Research during the past two decades has shown the existence of a superfamily of TNF proteins consisting of 19 members that signal through 29 receptors. These ligands, while regulating normal functions such as immune responses, haematopoiesis and morphogenesis, have also been implicated in tumorigenesis, transplant rejection, septic shock, viral replication, bone resorption, rheumatoid arthritis and diabetes; so indicating their role as 'double-edged swords'. These cytokines either induce cellular proliferation, survival, differentiation or apoptosis. Blockers of TNF have been approved for human use in treating TNF-linked autoimmune diseases in the United States and other countries.
引用
收藏
页码:745 / 756
页数:12
相关论文
共 126 条
  • [31] Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase -: Identification of a novel TRAF6 interaction motif
    Darnay, BG
    Ni, J
    Moore, PA
    Aggarwal, BB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (12) : 7724 - 7731
  • [32] The lymphotoxin-β receptor induces different patterns of gene expression via two NF-κB pathways
    Dejardin, E
    Droin, NM
    Delhase, M
    Haas, E
    Cao, YX
    Makris, C
    Li, ZW
    Karin, M
    Ware, CF
    Green, DR
    [J]. IMMUNITY, 2002, 17 (04) : 525 - 535
  • [33] Inflammatory mediators and the failing heart: A translational approach
    Diwan, A
    Tran, T
    Misra, A
    Mann, DL
    [J]. CURRENT MOLECULAR MEDICINE, 2003, 3 (02) : 161 - 182
  • [34] Current uses of isolated limb perfusion in the clinic and a model system for new strategies
    Eggermont, AMM
    de Wilt, JHW
    ten Hagen, TLM
    [J]. LANCET ONCOLOGY, 2003, 4 (07) : 429 - 437
  • [35] SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-α in the adipose tissue of obese mice
    Emanuelli, B
    Peraldi, P
    Filloux, C
    Chavey, C
    Freidinger, K
    Hilton, DJ
    Hotamisligil, GS
    Van Obberghen, E
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (51) : 47944 - 47949
  • [36] The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development
    Fata, JE
    Kong, YY
    Li, J
    Sasaki, T
    Irie-Sasaki, J
    Moorehead, RA
    Elliott, R
    Scully, S
    Voura, EB
    Lacey, DL
    Boyle, WJ
    Khokha, R
    Penninger, JM
    [J]. CELL, 2000, 103 (01) : 41 - 50
  • [37] A PHASE-I TRIAL OF INTRAVENOUSLY-ADMINISTERED RECOMBINANT TUMOR NECROSIS FACTOR-ALPHA IN CANCER-PATIENTS
    FEINBERG, B
    KURZROCK, R
    TALPAZ, M
    BLICK, M
    SAKS, S
    GUTTERMAN, JU
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (08) : 1328 - 1334
  • [38] Anti-TNFα therapy of rheumatoid arthritis:: what have we learned?
    Feldmann, M
    Maini, RN
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 : 163 - 196
  • [39] Fisher MJ, 2001, CLIN CANCER RES, V7, P1688
  • [40] Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
    Gardam, MA
    Keystone, EC
    Menzies, R
    Manners, S
    Skamene, E
    Long, R
    Vinh, DC
    [J]. LANCET INFECTIOUS DISEASES, 2003, 3 (03) : 148 - 155